tiprankstipranks
Trending News
More News >
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) AI Stock Analysis

Compare
470 Followers

Top Page

KP

Kiora Pharmaceuticals

(NASDAQ:KPRX)

Rating:56Neutral
Price Target:
Kiora Pharmaceuticals shows strong financial health with solid revenue growth and minimal debt, contributing positively to its stock score. However, weak technical indicators suggest bearish market sentiment, partially offsetting the financial strengths. The attractive valuation with a low P/E ratio presents potential upside, particularly if technical conditions improve.
Positive Factors
Financial Health
Kiora's strong balance sheet and collaboration with Théa leave the company well-funded as it prepares to launch Phase 2 studies for both of its lead assets.
Licensing Deals
Kiora Pharmaceuticals announced a license deal, selling commercial rights for KIO-301 in Asia to Senju Pharmaceutical Co., receiving an immediate $1.25M option fee and potential deal value of $110M.
Partnerships
The partnership with Senju increases the value of potential milestones to ~$400M, building on Kiora's existing collaboration with Théa for global rights ex-Asia.
Negative Factors
Clinical Trials
Risks include failure of KIO-301 in clinical trials and failure to secure regulatory approval.
Financial Performance
For 4Q24, net loss was $4.2M, higher than the estimated loss of $2.7M.
Market Competition
Risks include the failure of KIO-301 in clinical trials, to secure regulatory approval, or to achieve commercial success due to reimbursement, penetration rate, and competition.

Kiora Pharmaceuticals (KPRX) vs. SPDR S&P 500 ETF (SPY)

Kiora Pharmaceuticals Business Overview & Revenue Model

Company DescriptionKiora Pharmaceuticals (KPRX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for treating ophthalmic disorders. The company operates primarily in the healthcare sector, with a commitment to addressing unmet medical needs in the field of ophthalmology. Kiora's core products are designed to treat a range of eye diseases and conditions, offering potential solutions for patients suffering from vision impairment and blindness.
How the Company Makes MoneyKiora Pharmaceuticals generates revenue primarily through the sale and licensing of its ophthalmic products and therapies. The company's revenue model includes direct sales to healthcare providers, partnerships with pharmaceutical companies for the co-development and distribution of its products, and potential milestone payments and royalties from licensing agreements. These partnerships and collaborations are crucial as they provide access to broader markets and additional resources for research and development. Kiora's focus on innovative treatments for eye disorders positions it to capture a niche market, potentially leading to substantial revenue growth as its products gain regulatory approval and market acceptance.

Kiora Pharmaceuticals Financial Statement Overview

Summary
Kiora Pharmaceuticals exhibits a positive trajectory with substantial revenue growth and improved profitability in 2024. The company maintains strong financial stability with minimal leverage and a solid equity position. However, cash flow metrics indicate room for improvement in operational efficiency and cash management. The overall financial health is promising, with potential risks mitigated by strong equity foundations.
Income Statement
45
Neutral
Kiora Pharmaceuticals showed significant revenue growth in 2024 with a total revenue of $16.02 million compared to zero in previous years, indicating a positive turnaround. The gross profit margin is 100% for 2024, suggesting effective cost management. However, the net profit margin stands at 48.2%, hinting at some cost controls needing improvement. The EBIT margin is at 16.4%, but the absence of EBITDA data limits further analysis.
Balance Sheet
60
Neutral
The balance sheet reveals a solid equity position with a debt-to-equity ratio of 0.002, indicating minimal leverage and strong financial stability. The return on equity is 30%, reflecting efficient use of equity to generate profits. The equity ratio is 70.6%, suggesting a healthy balance between debt and equity financing.
Cash Flow
55
Neutral
The company experienced positive free cash flow in 2024, a substantial improvement from previous years. The free cash flow to net income ratio is 1.11, indicating strong cash generation relative to profits. However, the operating cash flow to net income ratio of 1.11 suggests that cash generation from operations aligns closely with net income, which may limit further cash flow leverage.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue20.00K16.02M0.000.000.0012.06K
Gross Profit-15.98M16.00M-4.03M-134.03K-227.27K-188.16K
EBITDA-9.84M5.75M-12.35M-13.55M-13.73M-6.65M
Net Income-12.05M3.59M-12.51M-13.58M-16.39M-8.09M
Balance Sheet
Total Assets34.02M36.48M13.71M18.68M18.06M15.16M
Cash, Cash Equivalents and Short-Term Investments24.11M26.79M2.45M5.96M7.85M1.19M
Total Debt159.02K57.17K106.89K105.78K209.41K362.12K
Total Liabilities10.32M10.72M7.60M7.27M8.83M8.16M
Stockholders Equity23.70M25.76M6.11M11.41M9.22M7.00M
Cash Flow
Free Cash Flow-7.78M8.55M-9.56M-10.43M-10.95M-7.45M
Operating Cash Flow-7.77M8.56M-9.56M-10.43M-10.89M-7.32M
Investing Cash Flow-19.99M-22.66M0.006.38K-157.02K-244.44K
Financing Cash Flow250.52K15.50M5.97M8.62M17.80M5.00M

Kiora Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.86
Price Trends
50DMA
3.11
Negative
100DMA
3.11
Negative
200DMA
3.32
Negative
Market Momentum
MACD
-0.08
Positive
RSI
43.44
Neutral
STOCH
32.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Negative. The current price of 2.86 is below the 20-day moving average (MA) of 3.01, below the 50-day MA of 3.11, and below the 200-day MA of 3.32, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 43.44 is Neutral, neither overbought nor oversold. The STOCH value of 32.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPRX.

Kiora Pharmaceuticals Risk Analysis

Kiora Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Kiora Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Kiora Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
¥338.68B10.98-2.99%2.59%11.79%-10.11%
56
Neutral
$8.55M4.67-41.13%
54
Neutral
$14.43M-195.46%-29.46%2.71%
45
Neutral
$9.43M-45.38%-48.61%32.18%
39
Underperform
$11.07M-285.79%23.65%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KPRX
Kiora Pharmaceuticals
2.86
-1.51
-34.55%
NURO
Neurometrix
4.58
0.87
23.45%
LYRA
Lyra Therapeutics
9.25
-5.38
-36.77%
ACXP
Acurx Pharmaceuticals
0.49
-1.72
-77.83%

Kiora Pharmaceuticals Corporate Events

Product-Related AnnouncementsRegulatory Filings and Compliance
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
Positive
Oct 29, 2024

Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 20, 2025